Gilead Sciences, Inc. vs Kinder Morgan Inc — how do they compare? Gilead Sciences, Inc. trades at $135.5 (market cap $168.35B), while Kinder Morgan Inc trades at $31.46 (market cap $70.10B). The key difference: Gilead Sciences, Inc. is far larger — about 2.4× Kinder Morgan Inc's market cap, and Kinder Morgan Inc pays the higher dividend (3.75%). Which is the better fit depends on your goals.
| GILD | KMI | |
|---|---|---|
Market Cap | $168.35B | $70.10B |
Sector | Health | Energy |
52-Week High | $155.80 | $34.31 |
52-Week Low | $110.56 | $25.84 |
Enterprise Value | $191.42B | $102.15B |
Dividend Yield | 2.42% | 3.75% |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →